Results about: iproteos

European project to develop an innovative therapeutic strategy against epilepsy

The European project «ECMED» (acronym of Extracellular Matrix in Epileptogenesis) is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy.

The project, which has a duration of three years and a budget of € 3.5 million, is co-funded by the European Union within the Horizon 2020 research and innovation framework program through a Marie Sklodowska-Curie grant.

Biotech Iproteos, –an spin-off the IRB Barcelona and the University of Barcelona, based at Parc Científic de Barcelona– is the only Spanish partner of the consortium.

«Spark», a new public-private project created to develop a drug to fight the cognitive impairment associated with schizophrenia

The goal of «Spark» is to carry out the first preclinical stage of the development of a first-in-class drug that will prevent, stop and reverse the progression of cognitive impairment associated with schizophrenia and other mental disorders, and to be able to start first-in-humans trials by 2016

The project, which has just won a 500,000 euro endorsement  from the Ministry of Economy and Finance and FEDER funds through the “Retos-Colaboración” (Challenges-Collaboration) subprogram- will be developed by a consortium led by the biotech Iproteos -located at the Parc Cientific de Barcelona- and comprised by the company Ascil-Biopharm, IRB Barcelona, the Centre for Genomic Regulation and the University of the Basque Country

Currently there is no drug targetting the cognitive impairment associated with schizophrenia, the third most disabling disease even above paraplegia and blindness- according to the WHO and that affects about 24 million people worldwide. It is also the fifth disease with a higher annual cost to society, with more than 35,000 million euros cost only in the Europe Union